We are live on
!
Find out more
OM
Opaleye Management Portfolio holdings
AUM
$1.1B
1-Year Est. Return
197.64%
This Fund
S&P 500
This Quarter
Est. Return
+0.58%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$602M
AUM Growth
-$78.7M
(-12%)
Cap. Flow
-$49.8M
Cap. Flow
% of AUM
-8.27%
Top 10 Holdings %
Top 10 Hldgs %
57.8%
Holding
63
New
5
Increased
16
Reduced
14
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kiniksa Pharmaceuticals
KNSA
|
+$12.7M |
| 2 |
Larimar Therapeutics
LRMR
|
+$8.22M |
| 3 |
GeneDx Holdings
WGS
|
+$4.86M |
| 4 |
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
|
+$4.59M |
| 5 |
Keros Therapeutics
KROS
|
+$4.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AUTL
Autolus Therapeutics
AUTL
|
+$12.1M |
| 2 |
Disc Medicine
IRON
|
+$11M |
| 3 |
CKPT
Checkpoint Therapeutics
CKPT
|
+$9.19M |
| 4 |
Immunovant
IMVT
|
+$7.49M |
| 5 |
Sanara MedTech
SMTI
|
+$7.01M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.85% |
| 2 | Financials | 0.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Dianthus Therapeutics
DNTH
$6.24B
| – | – |
-5,525
| Closed | -$1.05M |
|
|
FOCL
52
EDAP TMS S.A.
FOCL
$199M
| – | – |
-341,300
| Closed | -$2.87M |
|
|
KYNB
53
Kyntra Bio
KYNB
$32.4M
| – | – |
-5,880
| Closed | -$5.1M |
|
54
Gyre Therapeutics
GYRE
$708M
| – | – |
-166,667
| Closed | -$6.3M |
|
|
55
Immunovant
IMVT
$9.05B
| – | – |
-467,000
| Closed | -$7.49M |
|
|
56
Disc Medicine
IRON
$3.17B
| – | – |
-27,017
| Closed | -$11M |
|
57
Quantum-Si Incorporated
QSI
$176M
| – | – |
-241,300
| Closed | -$2.88M |
|
|
58
Sanara MedTech
SMTI
$318M
| – | – |
-225,000
| Closed | -$7.01M |
|
|
WHWK
59
Whitehawk Therapeutics
WHWK
$278M
| – | – |
-66,667
| Closed | -$1.29M |
|
|
ALPN
60
DELISTED
Alpine Immune Sciences Inc
ALPN
| – | – |
-156,500
| Closed | -$1.66M |
|
|
MYOV
61
DELISTED
Myovant Sciences Ltd.
MYOV
| – | – |
-249,800
| Closed | -$5.14M |
|
|
AYLA
62
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
| – | – |
-108,551
| Closed | -$1.18M |
|
|
BHVN
63
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| – | – |
-25,000
| Closed | -$1.71M |
|
Similar funds
CFO
PFM
HBCM
HAS
AI
TPA
ZDA
NW
Opaleye Management's Q2 2021 Portfolio in Review
As of Q2 2021, Opaleye Management held 63 positions worth $602M, down 12% from $681M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Opaleye Management withdrew a net $49.8M in Q2 2021, closing 15 positions and reducing 14 holdings. Its most notable exit was Autolus Therapeutics, an estimated $12.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.
Against the trend, Opaleye Management opened a new position in Larimar Therapeutics worth $7.15M.
- Opaleye Management's largest Q2 2021 buy was Larimar Therapeutics: 727,800 shares worth $7.15M.
- Opaleye Management added most to Kiniksa Pharmaceuticals in Q2 2021, an estimated $12.7M increase.
- Opaleye Management's biggest Q2 2021 reduction was BridgeBio Pharma, cutting an estimated $3.8M.
- Opaleye Management fully exited Autolus Therapeutics in Q2 2021, selling an estimated $12.1M.
- Opaleye Management's ten largest holdings make up 58% of its $602M portfolio in Q2 2021.
- Opaleye Management opened 5 new positions and closed 15 in Q2 2021.
- Opaleye Management's portfolio value fell 12% quarter-over-quarter to $602M.
Based on Opaleye Management's 13F filing for Q2 2021, filed 16 Aug 2021.